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Abstract
The caspase-3-generated RasGAP N-terminal fragment (fragment N) inhibits apoptosis in a Ras-PI3K-Akt-dependent manner.
Fragment N protects various cell types, including insulin-secreting cells, against different types of stresses. Whether
fragment N exerts a protective role during the development of type 1 diabetes is however not known. Non-obese diabetic
(NOD) mice represent a well-known model for spontaneous development of type 1 diabetes that shares similarities with the
diseases encountered in humans. To assess the role of fragment N in type 1 diabetes development, a transgene encoding
fragment N under the control of the rat insulin promoter (RIP) was back-crossed into the NOD background creating the
NOD-RIPN strain. Despite a mosaic expression of fragment N in the beta cell population of NOD-RIPN mice, islets isolated
from these mice were more resistant to apoptosis than control NOD islets. Islet lymphocytic infiltration and occurrence of a
mild increase in glycemia developed with the same kinetics in both strains. However, the period of time separating the mild
increase in glycemia and overt diabetes was significantly longer in NOD-RIPN mice compared to the control NOD mice.
There was also a significant decrease in the number of apoptotic beta cells in situ at 16 weeks of age in the NOD-RIPN mice.
Fragment N exerts therefore a protective effect on beta cells within the pro-diabetogenic NOD background and this
prevents a fast progression from mild to overt diabetes.
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Introduction
Apoptosis of pancreatic beta cells leads to type 1 diabetes [1,2]
and may contribute to the development of type 2 diabetes [3].
Apoptosis also mediates beta cell loss in islet transplantation both
during isolation of the islets [4] and during engraftment [5,6].
Finding ways of increasing the resistance of beta cells towards
apoptotic stimuli would therefore be beneficial in the context of
diabetes therapy.
We have characterized in the last few years an amino-terminal
RasGAP fragment, called fragment N, that protects various cell
types against a series of apoptotic stimuli [7–9]. Fragment N is
generated by the low caspase-3 activity found in stressed cells and
prevents further activation of caspases and apoptosis [8]. In the
presence of an apoptotic stimulus, fragment N is further cleaved by
caspase-3 and this abrogates its ability to protect cells [9]. It is
however possible to prevent this second cleavage by a point
mutation in the cleavage site at position 157 [7,9]. Fragment N
mediates its protection by activating the Ras-PI3K-Akt pathway
[10]. Despite the fact that Akt can activate the NFkB transcription
factor [11–13], NFkB stimulation does not occur when Akt is
activated by fragment N [10,14]. This could be beneficial for beta
cells because in contrast to what is found in many cell types,
sustained activation of NFkB in beta cells induces apoptosis
[15–18].
We have recently derived a transgenic mouse line in the FVB/N
background, called FVBN-RIPN, which expresses a caspase-
resistant form of fragment N under the control of the rat insulin
promoter (RIP). The presence of fragment N in the beta cells of
these mice confer resistance to streptozotocin-induced diabetes
[14] and islets isolated from RIPN mice are more resistant to cell
death induced by inflammatory cytokines, hyperglycemia, and
palmitate [14]. Importantly, the presence of fragment N in beta
cells neither impacts on their ability to secrete insulin in response
to increased glucose levels nor does it turn on their oncogenic
potential [14,19].
While the ability of fragment N to protect cells against acute
apoptotic stimuli has been well established, it is unclear whether
this beneficial effect could be observed in the context of a disease
that develops on a long-term basis through a progressive increase
in apoptosis in a given organ. We addressed this point here by
expressing fragment N in the NOD background. The NOD mice,
first described in the 1970s [20], represent a useful model of
spontaneous development of type 1 diabetes as it shares many
similarities with the diseases encountered in humans [21,22].
Development of diabetes in NOD mice starts by infiltration of
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immune cells into pancreatic islets. The infiltration is first detected
at the periphery of the islets (peri-insulinitis). This occurs around
3–5 weeks of age. Immune cells then invade the islets (insulinitis) so
that at 10 weeks of age, 100% of the mice develop severe
insulinitis. The tolerance of the infiltrated T cells towards the
antigens presented by beta cells is lost in 60–80% of females and
20–30% of males. These mice then experience massive beta cell
death and become overtly diabetic. Diabetes development in
NOD is driven by T cells because transfer of NOD T cells into
irradiated recipients allows the development of the disease,
although, interestingly, the T-cell mediated attack only takes
place in mice 6 weeks of age and older [23]. The extent of diabetes
development in NOD mice is greatly affected by earlier
stimulation of the immune system. For example, the incidence of
diabetes is highest when the mice are kept in germ-free animal
facilities and dramatically decreases when the mice are exposed to
foreign antigens encountered in conventional facilities [22].
Modulations of the immune system of young NOD mice can
therefore profoundly affect the immune attack on beta cells. This
could explain why so many treatments, by compromising the auto-
immune attack, prevent the development of diabetes in NOD mice
[22]. Consequently, treatments that affect auto-immunity in NOD
mice will not provide information on the mechanisms of beta cell
destruction that take place in the installation of type 1 diabetes.
The NOD model however is very suited to study mechanisms that
inhibit or block disease progression once insulinitis has occurred.
We present evidence here that fragment N does not affect the
extent of the immune attack in NOD mice but that it significantly
prolongs their ability to remain in an overt diabetes-free state once
their islets have started to be affected by auto-immune cells.
Materials and Methods
Ethics Statement
Experiments on the mice were carried out in strict accordance
with the Swiss Animal Protection Ordinance (OPAn). The
protocol was approved by the Veterinary office of the state of
Vaud, Switzerland (Permit Number: 2055).
Chemicals and antibodies
The Hoechst 33342 dye was purchased from Invitrogen (Basel,
Switzerland: catalog number H21492). Recombinant mouse IFNc
was from R&D systems (catalogue number 485-MI). Sodium
dodecyl sulfate (SDS) was form Bio-Rad (catalogue number 161-
0301). Deoxycholate was from Acros Organics/Thermo Fisher
Scientific (catalogue number 302-95-4). Recombinant mouse TNFa
was from Enzo Life Sciences (catalogue number ALX-522-009).
Dithiothreitol (DTT), Nonidet P-40 (NP40), poly(deoxyinosinic-
deoxycytidylic) acid sodium salt (poly dI-dC), HEPES, and
recombinant mouse IL-1b were from Sigma-Aldrich (catalogue
numbers 43817, I3021, P4929, H3537, and I5271, respectively).
Phenylmethylsulfonyl fluoride (PMSF) was from Pierce (catalogue
number 206-350-2). The monoclonal antibody specific for the
hemagglutinin (HA) tag was purchased as ascites from BabCo
(Richmond, CA; catalogue number MMS-101R). This antibody
was adsorbed on HeLa cell lysates to decrease non-specific binding
[7]. The anti-insulin guinea pig polyclonal IgG antibody (catalogue
number 4010-01) was from Linco Research Inc, (St. Charles, MO
USA). The anti-CD3 antibody directed at amino acids 156–168 of
the human CD3e chain was from Abcam (catalogue number
ab5690). The polyclonal rabbit anti-phospho Akt (serine 473)
antibody was from Cell Signaling (catalogue number 9271). The
rabbit polyclonal non-phospho-specific anti-Akt 1/2/3 antibody
(H-136) was from Santa-Cruz (catalogue number SC-8312). The
HRP conjugated anti-rabbit polyclonal antibody was from Jackson
ImmunoResearch (catalogue number 211-035-109). The FITC-
conjugated goat anti-guinea pig IgG polyclonal antibody (catalogue
number 106-095-003), Cy3-conjugated goat anti guinea pig
(catalogue number 106-165-003) and the Cy3-conjugated goat
anti-mouse IgG polyclonal antibody (catalogue number 115-165-
003) were from Jackson ImmunoResearch Europe (Suffolk, UK).
Buffers
Phosphate buffer saline (PBS): 116 mM NaCl, 10.4 mM
Na2HPO4, 3.2 mM KH2PO4 (pH 7.25).
Buffer A for nuclear extract preparation: 10 mM HEPES
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 0.5 mM DTT, 0.2 mM PMSF, and 0.5% NP40.
Buffer C for nuclear extract preparation: 20 mM HEPES
pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 10% glycerol, 1 mM PMSF.
Buffer R for EMSA: 10 mM HEPES (pH 7.9), 25 mM KCl,
0.25 mM DTT, 0.1% NP40, 10% glycerol, 1.5 mM MgCl2, and
0.1 mg/ml poly dI-dC.
RIPA buffer: 50 mM Tris-HCl (pH 8), 150 mM NaCl, 0.5%
deoxycholate, 1% NP40, 0.1% SDS, 1 mM PMSF.
Cell culture
The rat insulinoma INS1 cell line was cultured at 37uC and 5%
CO2 in RPMI-1640 (GIBCO; catalogue number 61870) contain-
ing 10% fetal bovine serum (GIBCO; catalogue number 10270-
106; lot nu41Q6001K), 1 mM sodium pyruvate (Sigma-Aldrich;
catalogue number S8636), and 50 mM beta-mercaptoethanol
(GIBCO; catalogue number 31350-010; lot nu493563). Isolated
islets were maintained in RPMI-1640 medium containing 10%
decomplemented fetal bovine serum, 10 mM HEPES, 2 mM
glutamine (Sigma-Aldrich; catalog number G-7513), 1 mM
sodium pyruvate (Sigma-Aldrich; catalog number S-8636) and
penicillin (100 units/ml)/streptomycin (100 mg/ml) (Invitrogen;
catalogue number 15140) at 37uC and 5% CO2.
Plasmids
The backbone vector pcDNA3 is from Invitrogen. Myr-mAkt1-
HA.cmv (#249), which encodes a constitutively active form of Akt
that bears a Src myristoylation sequence at its N-terminus and an
HA tag at its C-terminus, was described earlier under the name
myr-Akt.cmv [10]. Plasmid hIkB alpha delta N2.cmv (#11) encodes
the human IkBa protein with the DN2 deletion (i.e. amino acid 3–
71); this constructs cannot be phosphorylated by IkB kinases and
degraded by the proteasome and therefore functions as an inhibitor
of NFkB. It has been described before under the name of IkBaDN2
[10]. HA-hRasGAP 1–455 (D157A).dn3 (#352) encodes an HA-
tagged version of the uncleavable form of human fragment N
(described in [7] as N-D157A.dn3). prLUC (#49) is an NFkB
reporter plasmid. It contains two NFkB responsive elements
(AGGGGACTTTCCGA) and a minimal cFos promoter (nucleo-
tides 498–662 of the mouse cFos gene; locus MMCFOS) upstream
of the firefly luciferase. The pEGFP-C1 plasmid encoding the green
fluorescent protein (GFP) is from Clonetech.
Cell transfection
INS1 cells were transfected using lipofectamine 2000 (Invitro-
gen) with 0.5 mg of a GFP-expression plasmid (to label the
transfected cells) and 0.5 mg of the prLUC NFkB-reporter plasmid
together with 1 mg of the plasmids encoding the constructs
indicated in Figure 2C. The amount of DNA used in the
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22609
transfection was kept constant to 4 mg by the addition of
appropriate amounts of an empty vector (pcDNA3).
NFkB reporter assay
NFkB activity was measured using a luciferase reporter assay, as
described previously [24].
Transgenic lines
NOD/ShiLtJ-Tg(RIP::N)1Wid mice (abbreviated NOD-RIPN)
were obtained by backcrossing the RIPN transgene from FVB/N-
Tg(RIP::N)1Wid mice (corresponding to founder 1 in reference
[14]) into the NOD background using NOD/ShiLtJ mice (stock nu
001976; The Jackson Laboratory, Bar Harbor, Maine, USA).
During the first 5 generations, the progeny containing the highest
percentage of NOD genome was selected for further backcrossing.
The percentage of recipient genome was determined using the
GenoMouse service of Elchrom Scientific (Cham, Switzerland)
using 96 polymorphic microsatellite markers. After the fifth
generation, the percentage of NOD markers in the selected
progeny reached 98.9%. The back-crossing was further pursued
for two additional generations at which time the NOD-RIPN mice
were used in the described experiments.
PCR
DNA was isolated from tail or ear biopsies using the two-step
extraction ‘‘hotSHOT’’ method [25]. The presence of the
transgene was detected by PCR amplification of the isolated
DNA, as described previously [14].
Nuclear extract preparation
Nuclear extracts from islets were prepared as follows: 800 to 1’000
islets were collected in 1.5 ml Eppendorf tubes, washed twice with
800 ml of cold PBS (centrifuged at 2’300 g for 5 minutes in between
each wash). The pellet was resuspended in 400 ml ice-cold buffer A
in which protease inhibitors (Roche; catalogue number
04693132001) and phosphatase inhibitors (phosSTOP from Roche;
catalogue number 04906845001) were freshly added. The islet cells
were then incubated on ice for 15 minutes and vortexed 3 times for
15 seconds during the incubation period. After centrifugation for
2 minutes at 16’000 g, the pellets containing the nuclei were
resuspended in 35 ml of buffer C in which the same protease
inhibitors and phosphatase inhibitors as used in buffer A were freshly
added. The samples were then sonicated three times for 5 seconds at
an amplitude of 60% using a Vibracell 75186 sonicator (Thermo
Fisher Scientific; catalogue number W75186). The samples were
then incubated on ice for 20 minutes (the tubes were vortexed
15 seconds three times during this incubation period). Finally, the
samples were spun 5 minutes at 16’000 g in an Eppendorf
centrifuge and the supernatant stored at 280uC until used.
Electro-mobility shift assay (EMSA)
The oligonucleotides bearing the NF-kB binding elements
correspond to sequence AGC TTC AGA GGG GAC TTT CCG
AGA GGA GCT and CCT CTC GGA AAG TCC CCT CTG
AAG CTA GCT. Fourty mM of these oligonucleotides were
annealed overnight at room temperature in 50 ml of hybridization
buffer (2 mM Tris pH 7.4, 1 mM MgCl2, 5 mM NaCl). The
sticky ends of the annealed double stranded probes were filled
using the Klenow fragment of DNA polymerase I (Roche;
catalogue number 110 08 409 001) in the presence of
deoxycytosine (a-32P)-triphosphate (Hartmann Analytic GmbH;
catalogue number SRP-205-123349). The double stranded radio-
labeled probes were purified using the Qiagen QIAquick
Nucleotide removal kit (catalogue number 28304). Five mg of
nuclear proteins were mixed in 20 ml buffer R and incubated with
approximately 120 fmoles of the double-stranded labeled oligo-
nucleotides (NF-kB probe) for 20 min on ice. Samples were loaded
onto a 6% non-denaturing polyacrylamide gel with 0.56 Tris-
borate-EDTA buffer (0.5 mM EDTA, 22 mM boric acid, 22 mM
Tris-base). The gels were fixed in a solution of 10% acetic acid and
10% methanol, dried, and exposed to Hyperfilm-MP (Kodak).
Blood glucose measurement and diabetes incidence
measurement
Starting from five weeks of age, NOD and NOD-RIPN mice
were subjected to glycaemia measurement once a week.
Glycaemia was measured with the Accu-Check Compact plus
system (Roche, Mannheim, Germany) using a single drop of blood
taken from the tail vein. Mice were considered overtly diabetic if
their blood glucose levels were over 20 mM in two consecutive
measurements. This was a criterion for euthanasia. If no diabetes
developed, the mice were killed at 44 weeks of age.
Islet isolation
Islets were isolated as described previously [19]. For the
experiment described in Figure 2A, the islets were cultured in
complete culture medium (see cell culture section) for 22 hours
and then maintained in HBSS (GIBCO-Invitrogen; catalogue
number 240 20-091) complemented with 25 mM HEPES, 0.1%
BSA and 2.8 mM glucose for 2 additional hours. The islets were
then washed twice in PBS prior to lysis.
Western Blot
After isolation, islets were lysed on ice in mono Q-c buffer [7]
supplemented with one tablet of EDTA-free protease inhibitor per
50 ml (Figure 1A) or in RIPA buffer supplemented with one tablet of
phosphatase inhibitors (Roche; catalogue number 04 906 845 001)
per 50 ml (Figure 2A). Protein concentration was measured by
Bradford assay using BSA as a standard. Lysates were mixed with
sample buffer {62.4 mM Tris-HCl (pH 6.8), 10% glycerol, 5% b-
mercaptoethanol (v:v), 2% sodium dodecyl sulfate (w:v), and 0.01%
bromophenol blue} before loading on SDS-PAGE gels. Western
blotting was performed and quantitated as described previously [26].
Preparation of tissue section and immunohistochemistry
Histology sections were prepared as described previously [14].
Briefly, five, ten, and sixteen week-old mice were anesthetized
using 100 mg/kg pentobarbital injected i.p. (50 mg/ml, Lausanne
University Hospital, Switzerland, lot nu P08FA) and perfused with
150 ml of PBS containing 4% paraformaldehyde (PFA; Acros
Organics, catalog number 416780010). The isolated pancreata
were further fixed in PBS/4% PFA for 2 hours. After this fixation
step, pancreata were stored in PBS/4% formol solution and
embedded in paraffin. Eight mm sections were deparaffinized in
toluene (Carlo Erba, Milan, Italy, catalog number 488555,) and
rehydrated using graded alcohol and distilled water. Antigen
retrieval was performed by immersing sections in sodium citrate
buffer (10 mM sodium citrate pH 6), followed by heating in a
microwave for 20 minutes (8 min at 800 Watts and 12 minutes at
400 Watts). Sections were cooled down to room temperature,
blocked using a 50 mM Tris-HCl pH 7.6, 0.5% tween 20, 0.2%
BSA solution. The primary anti-CD3 antibody was diluted 1/200,
whereas the primary anti-insulin and anti-HA antibodies were
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diluted 1:100, in 50 mM Tris-HCl pH 7.6, 0.5% tween 20, 0.2%
BSA and incubated with the slides for 1 hour. Slides were washed
2 times 10 min in 50 mM Tris-HCl pH 7.6, 0.5% tween 20. The
fluorochrome-conjugated secondary antibody, diluted in 50 mM
Tris-HCl pH 7.6, 0.5% tween 20, 0.2% BSA, was incubated with
the slides for another hour in the dark. Slides were then extensively
washed (at least 6 times with one overnight washing step). The
nuclei in the sections were then stained with 10 mg/ml Hoechst
33342. Finally, the slides were mounted in Vectashield mounting
medium (Vector laboratories Inc, Burlingame, CA USA).
Immunohistochemistry tyramide signal amplification
Eight mm sections were processed as described above until the
antigen retrieval step. The endogenous peroxidase enzymes in the
paraffin sections were then inhibited with a 3% H2O2 solution for
10 minutes. Slides were washed 3 times in PBS, 0.05% tween 20
and then blocked in PBS, 0.05% tween 20, 0.2% BSA. The primary
anti-CD3 antibody was diluted 1/200 in the blocking solution and
incubated with the slides for 1 hour. Slides were washed 3 times
10 min in PBS, 0.05% tween 20. The HRP-coupled secondary
antibody, diluted 1/1000 in PBS, 0.05% tween 20, 0.2% BSA, was
incubated with the slides for another hour in the dark. Slides were
then washed 3 times in PBS, 0.05% tween 20 and incubated for
10 minutes in the dark with the Cy3 amplification reagent diluted
1/50 in 16 Plus Amplification Diluent according to the
manufacturer instructions (TSATM Plus Cyanine 3 System; Perkin
Elmer NEL744001KT). Slides were extensively washed in PBS,
0.05% tween 20 (4 times with one overnight washing step). The
nuclei in the sections were then stained with 10 mg/ml Hoechst
33342. Finally, the slides were mounted inMowiol (Fluka; catalogue
number 81381) at a concentration of 0.1 mg/ml in a solution made
of 20% glycerol and 0.1% DABCO (diazobiciclo-octane; Fluka;
catalogue number 33480).
Quantitation of CD3-positive cells within islets
Quantitation was performed with the NIS-Elements AR
program (Nikon) using the taxonomy tool of the ‘‘annotations
and measurements’’ menu. The total number of cells within an
islet (including infiltrating immune cells) was determined by
scoring the number of nuclei (stained with the Hoechst dye). The
number of T cells within islets was determined by scoring the
number of cells stained with the Cy3-labelled anti-CD3 antibody.
Whole section area quantitation
Sections stained as described in the previous sections were
scanned using an automated Nikon Eclipse 90i microscope
equipped with a 206objective and piloted with the NIS-Elements
Basic Research software (Nikon Instruments INC. Melville, USA).
The pictures were then converted to grayscale using Adobe
Photoshop Elements 5.0. They were then analyzed using the
ImageJ software (http://rsbweb.nih.gov/ij/) as follows: the area of
the whole pancreas was determined by setting a threshold to
remove the surface not occupied by tissues. The area of the insulin
positive cells was measured manually using the polygonal tool of
the software. The number of insulin positive cells within islets was
assessed manually by counting nuclei of the insulin positive cells.
The surface of individual insulin-containing cells was calculated by
dividing the area occupied by insulin-positive cells by the number
of insulin-positive cells in a given pancreatic section.
Apoptosis scoring
Apoptosis on histological slides was assessed by TUNEL assay
(DeadEnd Fluorometric TUNEL system, Promega Switzerland
Figure 1. Expression levels and functionality of the RIPN
transgene in NOD mice. A. Western blot analysis of lysates from
islets isolated from ten week-old female mice. The presence of fragment
N was assessed using an anti-HA antibody. B. Immunohistochemistry
analysis of paraffin sections of five week-old female mice. Sections were
stained using anti-insulin and anti-HA antibodies. Nuclei were stained
with Hoechst 33342. C. Freshly isolated islets from 5 week-old females
were incubated or not with inflammatory cytokines (1,000 units/ml
TNFa, 1,000 units/ml interleukin-1b, and 50 units/ml interferon-c)
during 24 hours. The islets were then stained with Hoechst 33342 and
apoptosis was scored.
doi:10.1371/journal.pone.0022609.g001
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catalog number G3250) on islet paraffin sections as per the
manufacturer’s protocol. Apoptosis ex vivo or in vitro was assessed by
scoring the number of cells with pycnotic nuclei after Hoechst
33342 staining [19]. In the case of INS1 cells, only the transfected
cells (i.e. expressing GFP) were scored.
Infiltration scoring
Lymphocytic infiltration was scored based on Hoechst 33342
staining of islet paraffin sections. Cells with small nuclei were
considered of haematopoietic origin. Infiltration scores were
determined as follows: 0, absence of small nuclei around or near
the islet, 1, presence of small nuclei around the islet but no or very
limited infiltration, 2, up to one third of the islet infiltrated with
cells with small nuclei, 3, between one third to two thirds of the
islet infiltrated with cells with small nuclei; and 4, more than two
thirds of the islet infiltrated with cells with small nuclei.
Statistics
The SAS/STAT v9.1 software (SAS Institute Inc., Cary, NC,
USA) was used to perform the statistical analyses. Two-sided
Figure 2. Signals modulated by fragment N. A. The extent of Akt activation was assessed by Western blot analysis of 10 mg of lysates from islets
isolated from 5 week-old female mice using an antibody recognizing the phosphorylated form of Akt. Total levels of Akt were also determined using a
non-phospho-specific anti-Akt antibody. B. Islets isolated from NOD and NOD-RIPN mice were stimulated or not for 30 minutes with inflammatory
cytokines (1,000 units/ml tumor necrosis factor-a, 1,000 units/ml interleukin-1b, and 50 units/ml interferon-c). The ability of nuclear proteins to interact
with an NFkB-binding element-bearing radioactive probe was then monitored by EMSA as described in the methods. The locations of p65-p50 and p50-
p50 complexes are indicated. The asterisk denotes a nonspecific band. C. INS1 cells were transfected with an empty vector (pcDNA3), a plasmid
encoding the myristoylated active form of Akt (myr-Akt), a plasmid encoding a super NFkB repressor (IkBaDN2), or a plasmid encoding fragment N in the
indicated combinations, together with a NFkB-reporter luciferase construct and a GFP-encoding plasmid (to label the transfected cells). One day after,
transfection, the cells were lysed to assess NFkB activity (left panel). Alternatively, apoptosis was scored in the transfected cells (right panel).
doi:10.1371/journal.pone.0022609.g002
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Wilcoxon two-sample tests were used in Figure 3. For figures 4A
and B, Wilcoxon tests of equality over strata (life-test procedure)
were performed. Fisher exact tests were used to analyze the data
shown in Figures 4D. The remaining data were analyzed using
student t tests with Bonferonni corrections. Asterisks and ‘‘NS’’ in
the figures indicate significant differences and no significant
differences, respectively. Unless otherwise stated, results are
derived from triplicate determinations (from three independent
experiments) or three animals per condition and are presented as
means 695% confidence intervals (95% CI).
Figure 3. Lymphocytic infiltration. A. Paraffin sections of female mice of the indicated ages were stained with Hoechst 33342. Infiltration was
scored as described in the methods. The upper images depict representative examples of the different infiltration grades (the white dotted lines
delineate the islets and the red dotted lines encircle the lymphocytic infiltration). B. Paraffin sections of infiltration grade 2 islets of 10 weeks old NOD
and NOD-RIPN mice were stained with an anti-CD3 specific antibody (orange). The nuclei were stained with Hoechst 33342 (blue). Quantitation of
CD3-positive cells relative to the total number of islet cells is shown on the right. Note that T cells (i.e. CD3-positive cells) are smaller than islet cells.
Hence T cells making about 50% of the total number of cells within islets occupy an islet area that is less than half.
doi:10.1371/journal.pone.0022609.g003
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Results
Expression of fragment N in pancreatic beta cells of NOD
mice
The RIPN transgene encoding the HA-tagged form of the
D157A caspase-resistance fragment N form under the control of
the rat insulin promoter (RIP) [14] was backcrossed into the NOD
background (see materials and methods), generating NOD-RIPN
mice. Table 1 indicates that the size of islets and islet cells, the
number of insulin-positive cells per islet, and the number of islets
per section were not affected by the RIPN transgene. Figure 1A
shows that fragment N is expressed in islets isolated from NOD-
RIPN albeit to lower levels compared to mice expressing the
transgene in the FVBN background (FVBN-RIPN mice). This
weaker expression likely results from a mosaic expression of the
transgene in the NOD background. Indeed, in contrast to what is
seen in FVBN-RIPN mice where close to 100% of insulin-
expressing cells express the RIPN transgene [14], only 44614%
(mean 695%CI; 58 islets from 6 five week-old NOD-RIPN mice)
of the insulin positive cells were expressing the transgene (i.e. were
HA-positive) (see Figure 1B for a representative example of this
mosaicism). Despite this, islets isolated from NOD-RIPN mice
Figure 4. Diabetes development. The glycaemia of non-fasted mice (20 NOD females, 14 NOD-RIPN females, 16 NOD males, and 30 NOD-RIPN
males) was measured once a week. Mice with glycaemia under 10 mM were considered normo-glycaemic and those with a glycaemia over 20 mM
were considered diabetic. A. Normo-glycaemia curves. B. Diabetes-free curves. C. Glycaemia of individual mouse preceding the development of
overt diabetes. Time 0 corresponds to the time when the mice had a glycaemia over 10 mM for the first time. D. Panel C was used to determine the
percentage of mice that had glycaemia over 10 mM for the indicated number of weeks before becoming overtly diabetic.
doi:10.1371/journal.pone.0022609.g004
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were nevertheless significantly more resistant to inflammatory
cytokine-induced apoptosis compared to islets isolated from NOD
control mice (Figure 1C). This indicates that fragment N is
functional in its ability to induce protective signals in beta cells of
NOD mice.
Protective signaling induced by fragment N in beta cells
The anti-apoptotic kinase Akt is required for N to exert its
protective functions both in beta cell lines and non-beta cells
[8,10,19]. Figure 2A shows that this kinase is, as expected,
constitutively activated in islets isolated from NOD-RIPN mice.
While Akt has the ability to stimulate the NFkB transcription
factor, it does not so in the presence of fragment N [10].
Moreover, the presence of fragment N in beta cells of FVB/N
mice hampers NFkB stimulation by cytokines [14] and the same is
observed in islets isolated from NOD-RIPN mice (Figure 2B). This
might be important in the context of pancreatic beta cell survival
as sustained activation of NFkB induces the death of beta cells
[27]. Indeed, inhibition of NFkB specifically in beta cells in vivo,
protects mice from developing multiple low-dose streptozotocin-
induced diabetes [18]. To evaluate the potential beneficial effect of
blocking NFkB when Akt is stimulated in insulin secreting cells,
INS1 were transfected with a plasmid encoding a constitutive form
of Akt (myr-Akt) with or without plasmids encoding either
fragment N or a super-repressor of NFkB (a truncated version of
IkBa that cannot be degraded and hence that chronically binds to
and inhibits NFkB). Figure 2C shows that expression of myr-Akt
stimulates NFkB activity in INS1 cells but this also induces their
apoptosis. However, blocking NFkB activity with the NFkB super-
repressor or with fragment N (Figure 2C, left panel) restores the
viability of INS1 cells expressing myr-Akt (Figure 2C, right panel).
This indicates that fragment N, through its capacity to inhibit
NFkB, prevents beta cell death induced by an active form of Akt.
However, Akt is required for fragment N to mediate its protective
function in beta cells [19]. Therefore, in the case of beta cells, both
activation of Akt and blockade of NFkB appear required for an
efficient protection induced by fragment N.
The effect of fragment N expression on type 1 diabetes
development
To determine if the RIPN transgene could affect the auto-
immune islet attack occurring in the NOD background, the extent
of lymphocytic infiltration was scored (see material and methods)
at 5, 10, and 16 weeks of age. Figure 3A shows a significant
increase in lymphocyte infiltration in mice of both genotypes
between 5 and 10 weeks of age. The lymphocyte infiltration
however did not differ between NOD and NOD-RIPN mice.
Additionally, the percentage of T cells (i.e. CD3-positive cells) in
the infiltrated area did not differ between the two strains of mice
(Figure 3B). The kinetics and mode of activation of the auto-
immune attack on islets therefore does not seem to be affected by
the presence of fragment N in beta cells of NOD mice.
To determine whether fragment N modulates the development
of diabetes due to the NOD background, cohorts of male and
female NOD and NOD-RIPN mice were followed for their
glycaemia up to 44 weeks of age (Figure 4). During this period
,90% of the females and ,50% of the males, irrespectively of the
presence of the RIPN transgene, developed diabetes. There was
no statistical difference between the NOD and NOD-RIPN mice
in terms of reduction over time of the number of mice with normo-
glycaemia (non-fasted glycaemia below 10 mM; Figure 4A) or
mice without overt diabetes (non-fasted glycaemia below 20 mM;
Figure 4B). There was a clear trend in NOD-RIPN males,
however, to maintain a glycaemia between 10 and 20 mM and,
even more strikingly, to become overtly diabetic later than NOD
controls (Figure 4A–B).
Table 1. Pancreatic histological sections from mice of the indicated age stained with anti-insulin antibodies and with Hoechst
33342 were used to determine the indicated parameters (see material and methods).
Week 5 Parameter NOD NOD-RIPN
Area of insulin positive cells (% of pancreas section) 0.6160.26 0.8960.12
Single islet surface (mm2) 386861804 44716996
Number of insulin positive cells per islet 1968 2164
Number of islets per section 2967 37612
Area of a single insulin positive cell (mm2) 202641 211634
Week 10 Parameter NOD NOD-RIPN
Area of insulin positive cells (% of pancreas section) 0.5060.15 0.7760.43
Single islet surface (mm2) 499862122 467361667
Number of insulin positive cells per islet 2069 2066
Number of islets per section 3369 34611
Area of a single insulin positive cell (mm2) 251611 231630
Week 16 Parameter NOD NOD-RIPN
Area of insulin positive cells (% of pancreas section) 0.3760.23 0.3760.21
Single islet surface (mm2) 444761966 485662281
Number of insulin positive cells per islet 20611 26614
Number of islets per section 17611 19614
Area of a single insulin positive cell (mm2) 184627 188643
Six female mice per genotype and per age were used (one section per animal). The results are represented as mean695% CI. There was no statistical significant
difference between NOD and NOD-RIPN mice as assessed by Student t test for any of the tested parameter.
doi:10.1371/journal.pone.0022609.t001
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Figure 1 showed that ,40% of beta cells in the NOD-RIPN
mice did not express the transgene, suggesting that half of the
insulin-secreting cells in these mice will not benefit from the
potential protection conferred by fragment N. As the auto-
immune attack on islet cells does not seem to be affected by
fragment N (see Figure 3), this could explain why the kinetics of
appearance of a glycaemia over 10 mM was not significantly
different between NOD and NOD-RIPN mice (Figure 4A). The
stochastic nature of appearance of diabetes in the NOD model
[20], combined with the partial penetrance of fragment N
expression in NOD-RIPN mice, could explain the lack of
significance in the development of overt diabetes between NOD
and NOD-RIPN mice (Figure 4B). However, when taken
individually, NOD-RIPN mice were found to remain in an
overtly diabetes-free condition (i.e. non-fasted glycaemia below
20 mM) significantly longer than the NOD controls once their
glycaemia exceeded 10 mM for the first time (Figure 4C–D). This
was particularly striking in males. This protective effect of
fragment N was also seen when apoptosis in situ was assessed in
insulin-containing cells in 16 week-old mice (Figure 5).
Discussion
In the present work, we provide evidence that fragment N
expressed in ,40% of the pancreatic beta cells of NOD mice
significantly increases the time these mice can remain free of overt
diabetes (.20 mM) once they have started to lose their ability to
maintain a normo-glycaemia (i.e. ,10 mM). Presumably, this
protective effect would have been greater were fragment N
expressed in more beta cells. The reason why the transgene
encoding fragment N is expressed in virtually all beta cells of FVB/
Nmice [14] but less than half of the beta cells after the back-cross in
the NOD background is unclear. There are however precedents for
such observations. For example, the expression in beta cells of a
transgene coding for the myristoylated active form of Akt was
initially reported to be close to 100% [28] but became mosaic when
it was further backcrossed into the C57BL/6 background [29].
T cell-mediated apoptosis of beta cells is the cause of
development of type 1 diabetes [30]. In recently diagnosed type
1 diabetic patients, a residual population of beta cells appear to
remain however and there is even evidence that there is on-going
beta cell production in long-standing type 1 diabetes (discussed in
reference [31]). While there is no information on the mechanisms
that could potentially mediate beta cell replication or beta cell
differentiation in adult human individuals, work performed in
mice has revealed at least two independent ways that can lead to
an increase in beta cell mass in rodents: replication from pre-
existing beta cells [32,33] and trans-differentiation from glucagon
producing alpha cells [34]. In the context of immuno-suppression,
it is interesting to note that proliferation of a pre-existing beta cell
pool is inhibited by the non-steroid immuno-suppressant drugs
used during islet transplantation [33], a very unfortunate side
effects of these drugs that could block a potential capacity of the
grafted islets to increase their number of beta cells.
Figure 5. Apoptosis in situ. Mice at the indicated ages were killed and apoptosis of insulin-expressing cells on islet sections was determined by the
TUNEL assay. A. Examples of early and late apoptotic cells as well as apoptotic bodies (white arrowheads). The structure indicated by the red
arrowhead is not considered as an apoptotic cell because it does not contain DNA (i.e. not stained with the Hoechst dye). Such structures are not
included in the quantitation shown in panel B. B. Representative images of whole islet sections from 16 week-old animals stained for insulin and DNA
and subjected to TUNEL. C. Quantitation of TUNEL-positive cells within the insulin-containing cell population. Results are derived from 5–6 mice per
age group and genotype.
doi:10.1371/journal.pone.0022609.g005
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Regardless of the underlying mechanisms that would allow a
therapeutic treatment to favor an increase in beta cell mass in type
1 diabetic patients, raising the intrinsic resistance of beta cells to
apoptosis should in principle provide an additional benefit to the
treatment.
Apoptosis has been reported to occur before the lymphocytic
infiltration in islets of NOD mice [35]. Fragment N through its
ability to inhibit apoptosis could therefore have had a negative
effect on the development of insulinitis that could explain its ability
to delay diabetes development in the NOD background. However,
NOD-RIPN mice experienced the same extent of immune
infiltration as control NOD mice (Figure 3) and there was no
difference in the rate of beta cell apoptosis before immune
infiltration (Figure 5). Fragment N does not therefore affect the
events that will induce the auto-immune attack on beta cells in
NOD mice but it protects beta cells against the infiltrated immune
cells.
Other anti-apoptotic proteins than fragment N have been tested
in the NOD background for their ability to protect beta cells
against apoptosis. CrmA is a viral protein of the serpin family that
potently inhibits caspases [36]. When expressed in beta cells of
NOD mice this protein led to a reduction in the spontaneous
development of diabetes [37]. The use of CrmA as a protective
device in beta cells would however be problematic because of the
potential immune reaction that can be induced by a viral protein.
Bcl-2 is the prototypic member of the Bcl-2 family of proteins [38].
It inhibits the activity of pro-apoptotic Bcl-2 family members and
can prevent cell death of cells in response to a variety of stimuli. It
has no effect however on the development of diabetes when
expressed in the beta cells of NOD mice [39]. Fragment N is
therefore a better beta-cell protector in vivo compared to Bcl-2,
which is consistent with in vitro data obtained using the insulinoma
cell lines betaTC-tet [19]. If combined with treatments aimed at
reducing the strength of the autoimmunity, tools based on the
ability of fragment N to protect beta cells could contribute to
maintain an appropriate glucose control in patients who might
otherwise become diabetic.
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